Axial spondyloarthritis
Clinical research at Rheumazentrum Ruhrgebiet in Herne is centered on the management of axial spondyloarthritis, with attention to both established and very early inflammatory disease. The trials reflect interest in symptom control, reduction of disease activity, and treatment strategies for patients who do not respond adequately to initial anti-inflammatory therapy.
- Nonsteroidal anti-inflammatory drugs in outpatient care
- TNF blockers for inflammatory spine disease
- Early intervention in active axial spondyloarthritis
The sponsor also supports research into treatment selection for patients with persistent inflammatory symptoms, including comparative evaluation of biologic therapy and standard anti-inflammatory approaches.
Biologic therapy in inflammatory rheumatic disease
Another area of interest is biologic treatment for rheumatic disease, especially therapies targeting key immune pathways involved in spondyloarthritis. The funded studies include investigation of TNF inhibition and IL-23 inhibition in relation to inflammatory control and clinical response.
- TNF inhibition
- IL-23 pathway
- Immune-mediated inflammation
These research efforts align with a focus on therapeutic options that address persistent inflammation in patients with active spinal and musculoskeletal involvement.
